Chitosan surface-modified hydroxycamptothecin loaded nanoparticles with enhanced transport across caco-2 cell monolayer

Journal of Nanoscience and Nanotechnology

Volumn 6, Issue 9-10, 2006, Pages 2912-2920

  Zhang, Leyang ^a   Sun, Minjie ^a   Guo, Rui ^a   Jiang, Zhiping ^a   Liu, Yun ^a   Jiang, Xiqun ^a   Yang, Changzheng ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Antitumor; Caco 2 Cells; Camptothecin; Nanoparticles; Oral Delivery

Indexed keywords

ANTITUMOR; CACO-2 CELLS; CAMPTOTHECIN; ORAL DELIVERY;

BIODEGRADATION; CELLS; CONTROLLED DRUG DELIVERY; LIGHT SCATTERING; MONOLAYERS; SURFACE TREATMENT;

NANOSTRUCTURED MATERIALS;

10 HYDROXYCAMPTOTHECIN; 10-HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BIOMATERIAL; CAMPTOTHECIN; CHITOSAN; DRUG CARRIER; DRUG DERIVATIVE; NANOMATERIAL;

ACTIVE TRANSPORT; ARTICLE; CELL STRAIN CACO 2; CHEMISTRY; COMPARATIVE STUDY; CRYSTALLIZATION; HUMAN; MATERIALS TESTING; METHODOLOGY; PARTICLE SIZE; SURFACE PROPERTY; ULTRASTRUCTURE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL TRANSPORT, ACTIVE; CACO-2 CELLS; CAMPTOTHECIN; CHITOSAN; COATED MATERIALS, BIOCOMPATIBLE; CRYSTALLIZATION; DRUG CARRIERS; HUMANS; MATERIALS TESTING; NANOSTRUCTURES; PARTICLE SIZE; SURFACE PROPERTIES;

EID: 33750046646     PISSN: 15334880     EISSN: None     Source Type: Journal    
DOI: 10.1166/jnn.2006.431     Document Type: Conference Paper

References (42)

1. A. Bottomley, The Oncologist 7, 120 (2002).
2. M. DeMario and M. Ratain, J. Clin. Oncol. 16, 2557 (1998).
3. C. Gerrits, H. Burris, J. Schellens, J. Eckardt, A. Planting, M. Van der Burg, G. Rodriguez, W. Loos, V. Van Beurden, I. Hudson, S. Fields, D. Von Hoff, and J. Verweij, Clin. Cancer Res. 4, 1153 (1998).
4. P. Houghton, P. Cheshire, J. Hallman, L. Lutz, H. Friedman, M. Danks, and J. Houghton, Cancer Chemother. Pharmacol. 36, 393 (1995).
5. M. Malingre, J. Beijnen, and J. Schellens, Invest. New Drugs 19, 155 (2001).
6. D. Zhong, K. Li, J. Xu, Y. Du, and Y. Zhang, Acta Pharmacol. Sin. 24, 256 (2003).
7. A. Sparreboom, J. Van Asperen, U. Mayer, A. Schinkel, J. Smit, D. Meijer, P. Borst, W. Nooijen, J. Beijnen, and O. Van Tellingen, Natl. Acad. Sci. USA 94, 2031 (1997).
8. F. Luo, P. Paranjpe, A. Guo, E. Rubin, and P. Sinko, Drug Metab. Distri. 30, 763 (2002).
9. E. Gupta, F. Luo, A. Lallo, S. Ramanathan, V. Vyas, E. Rubin, and P. Sinko, Anticancer Res. 20 (2A), 1013 (2000).
10. C. Kruijtzer, J. Beijnen, H. Rosing, W. Bokkel, M. Schot, R. Jewell, E. Panl, and J. Schellens, J. Clin. Oncol. 20, 2943 (2002).
11. M. Malingre, J. Beijnen, H. Rosing, F. Koopman, O. Van Tellingen, K. Duchin, W. Huinink, M. Swart, J. Lieverst, and J. Schellens, AntiCancer Drugs 12, 351 (2001).
12. J. Terwogt, J. Beijnen, W. Huinink, H. Rosing, and J. Schellens, Lancet 352, 285 (1998).
13. C. Stewart, M. Leggas, J. Schuetz, J. Panetta, P. Cheshire, J. Peterson, N. Daw, J. Jenkins, R. Gilbertson, G. Germain, F. Harwood, and P. Houghton, Cancer Res. 64, 7491 (2004).
14. H. Chen and R. Langer, Adv. Drug Deliv. Rev. 34, 339 (1998).
15. T. Jung, W. Kamm, A. Breitenbach, E. Kaiserling, J. Xiao, and T. Kissel, Eur. J. Pharm. Biopharm. 50, 147 (2000).
16. H. Takeuchi, H. Yamamoto, and Y. Kawashima, Adv. Drug Deliv. Rev. 47, 39 (2001).
17. A. Florence, A. Hillery, N. Hussain, and P. Jani, J. Control. Rel. 36, 39 (1995).
18. I. Van der Lubben, J. Verhoef, A. Van Aelst, G. Borchard, and H. Junginger, Biomaterials 22, 687 (2001).
19. D. Norris, N. Puri, and P. Sinko, Adv. Drug Deliv. Rev. 34, 135 (1998).
20. P. Calvo, J. Vila-Jato, and M. Alonso, Intl. J. Pharm. 153, 41 (1997).
21. H. Takeuchi, Y. Matsui, H. Yamamoto, and Y. Kawashima, J. Control. Rel. 86, 235 (2003).
22. C. Prego, M. Garcia, D. Torres, and M. Alonso, J. Control. Rel. 101, 151 (2005).
23. K. Win and S. Feng, Biomaterials 26, 2713 (2005).
24. B. Rege, J. Kao, and J. Polli, Eur. J. Pharm. Sci. 16, 237 (2002).
25. S. Yang, J. Zhu, Y. Lu, B. Liang, and C. Yang, Pharm. Res. 16, 751 (1999).
26. L. Zhang, Y. Hu, X. Jiang, C. Yang, W. Lu, and Y. Yang, J. Control. Rel 96, 135 (2004).
27. G. Ranaldi, I. Marigliano, I. Vespignani, G. Perozzi, and Y. Sambuy, J. Nutritional Biochem. 13, 157 (2002).
28. A. Shenderova, T. G. Burke, and S. Schwendeman, Pharm. Res. 14, 1406 (1997).
29. A. Quaroni and J. Hochman, Adv. Drug Deliv. Rev. 22, 3 (1996).
30. L. Gan and D. Thakker, Adv. Drug Deliv. Rev. 23, 77 (1997).
31. Y. Dong and S. Feng, Biomaterials 26, 6068 (2005).
32. M. Wall, M. Wani, C. Cook, K. Palmer, A. McPhail, and G. Sim, J. Am. Chem. Soc. 88, 3888 (1966).
33. A. Schultz, Chem. Rev. 73, 385 (1973).
34. R. Garcia-Carbonero and J. Supko, Clin. Cancer Res. 8, 641 (2002).
35. D. Xie, Y. Hu, Q. Shen, and C. Yang, J. Appl. Polym. Sci. 72, 667 (1999).
36. P. Artursson and J. Karlsson, Biochem. Biophys. Res. Commun. 175, 880 (1991).
37. W. Rubas, N. Jezyk, and G. Grass, Pharm. Res. 10, 113 (1993).
38. X. Sha and X. Fang, Intl. J. Pharm. 272, 161 (2004).
39. X. Chu, H. Suzuki, K. Ueda, Y. Kato, S. Akiyama, and Y. Sugiyama, J. Pharmacol. Exp. Ther. 288, 735 (2000).
40. Y. Sugiyama, Y. Kato, and X. Chu, Cancer Chemother. Pharmacol 42, S44 (1998).
41. M. Thanou, J. Verhoef, and H. Junginger, Adv. Drug Deliv. Rev. 50, S91 (2001).
42. M. Desai, V. Labhasetwar, E. Walter, R. Levy, and G. Amidon, Pharm. Res. 14, 1568 (1997).